Business Description
Questcor Pharmaceuticals Inc
ISIN : US74835Y1010
Compare
Compare
Traded in other countries / regions
QPH.Germany Description
Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 26.39 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 241.04 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 14.52 | |||||
| Beneish M-Score | -2.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 94 | |||||
| 3-Year EBITDA Growth Rate | 106.4 | |||||
| 3-Year EPS without NRI Growth Rate | 106.6 | |||||
| 3-Year FCF Growth Rate | 113.4 | |||||
| 3-Year Book Growth Rate | 51.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.17 | |||||
| Quick Ratio | 3.08 | |||||
| Days Inventory | 69.85 | |||||
| Days Sales Outstanding | 39.63 | |||||
| Days Payable | 159.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.27 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| 5-Year Yield-on-Cost % | 1.27 | |||||
| 3-Year Average Share Buyback Ratio | 1.7 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.32 | |||||
| Operating Margin % | 54.73 | |||||
| Net Margin % | 36.05 | |||||
| FCF Margin % | 41.57 | |||||
| ROE % | 85.24 | |||||
| ROA % | 47.94 | |||||
| ROIC % | 199.46 | |||||
| ROC (Joel Greenblatt) % | 1414.97 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.37 | |||||
| Forward PE Ratio | 12.76 | |||||
| PE Ratio without NRI | 16.37 | |||||
| Shiller PE Ratio | 41.36 | |||||
| PEG Ratio | 0.17 | |||||
| PS Ratio | 5.91 | |||||
| PB Ratio | 10.12 | |||||
| Price-to-Free-Cash-Flow | 14.2 | |||||
| Price-to-Operating-Cash-Flow | 13.85 | |||||
| EV-to-EBIT | 9.97 | |||||
| EV-to-EBITDA | 9.62 | |||||
| EV-to-Revenue | 5.45 | |||||
| Earnings Yield (Greenblatt) % | 10 | |||||
| Forward Rate of Return (Yacktman) % | 95.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Questcor Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 723.505 | ||
| EPS (TTM) (€) | 4.19 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 47.71 - 97.8 | ||
| Shares Outstanding (Mil) | 60.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Questcor Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Questcor Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Questcor Pharmaceuticals Inc Frequently Asked Questions
What is Questcor Pharmaceuticals Inc(FRA:QPH)'s stock price today?
The current price of FRA:QPH is €68.61. The 52 week high of FRA:QPH is €97.80 and 52 week low is €47.71.
When is next earnings date of Questcor Pharmaceuticals Inc(FRA:QPH)?
The next earnings date of Questcor Pharmaceuticals Inc(FRA:QPH) is .
Does Questcor Pharmaceuticals Inc(FRA:QPH) pay dividends? If so, how much?
The Dividend Yield %  of Questcor Pharmaceuticals Inc(FRA:QPH) is 1.27% (As of Today), Highest Dividend Payout Ratio of Questcor Pharmaceuticals Inc(FRA:QPH) was 0.39. The lowest was 0.16. And the median was 0.22. The  Forward Dividend Yield % of Questcor Pharmaceuticals Inc(FRA:QPH) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers